Cheng H - Search Results

1

Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity.

Cheng H, Cao X, Xian M, Fang L, Cai TB, Ji JJ, Tunac JB, Sun D, Wang PG. Cheng H, et al. J Med Chem. 2005 Jan 27;48(2):645-52. doi: 10.1021/jm049693a. J Med Chem. 2005. PMID: 15658879

2

Syntheses and biological activities of rebeccamycin analogues with uncommon sugars.

Zhang G, Shen J, Cheng H, Zhu L, Fang L, Luo S, Muller MT, Lee GE, Wei L, Du Y, Sun D, Wang PG. Zhang G, et al. Among authors: cheng h. J Med Chem. 2005 Apr 7;48(7):2600-11. doi: 10.1021/jm0493764. J Med Chem. 2005. PMID: 15801850

3

Syntheses and biological activities of disaccharide daunorubicins.

Zhang G, Fang L, Zhu L, Aimiuwu JE, Shen J, Cheng H, Muller MT, Lee GE, Sun D, Wang PG. Zhang G, et al. Among authors: cheng h. J Med Chem. 2005 Aug 11;48(16):5269-78. doi: 10.1021/jm050144u. J Med Chem. 2005. PMID: 16078845

4

Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.

Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW Jr, Wang PG, Sun D. Fang L, et al. Among authors: cheng h. J Med Chem. 2006 Oct 19;49(21):6290-7. doi: 10.1021/jm060647f. J Med Chem. 2006. PMID: 17034135 Free PMC article.

5

Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model.

Cao X, Jia G, Zhang T, Yang M, Wang B, Wassenaar PA, Cheng H, Knopp MV, Sun D. Cao X, et al. Among authors: cheng h. Cancer Chemother Pharmacol. 2008 Nov;62(6):985-94. doi: 10.1007/s00280-008-0688-8. Epub 2008 Feb 6. Cancer Chemother Pharmacol. 2008. PMID: 18253734

6

Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.

Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D. Cao X, et al. Among authors: cheng h. Clin Cancer Res. 2008 Mar 15;14(6):1831-9. doi: 10.1158/1078-0432.CCR-07-1607. Clin Cancer Res. 2008. PMID: 18347186

7

Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment.

Hou Y, Kuang W, Min W, Liu Z, Zhang F, Yuan K, Wang X, Sun C, Cheng H, Wang L, Xiao Y, Pu S, Xin GZ, Yang P. Hou Y, et al. Among authors: cheng h. J Med Chem. 2021 Oct 28;64(20):14942-14954. doi: 10.1021/acs.jmedchem.1c00087. Epub 2021 Oct 13. J Med Chem. 2021. PMID: 34644502

8

Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia.

Ge H, Zhang W, Yuan K, Xue H, Cheng H, Chen W, Xie Y, Zhang J, Xu X, Yang P. Ge H, et al. Among authors: cheng h. Eur J Med Chem. 2021 Oct 5;221:113522. doi: 10.1016/j.ejmech.2021.113522. Epub 2021 May 5. Eur J Med Chem. 2021. PMID: 33984804

9

Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.

Cheng H, Zhang L, Liu Y, Chen S, Cheng H, Lu X, Zheng Z, Zhou GC. Cheng H, et al. Eur J Med Chem. 2010 Dec;45(12):5950-7. doi: 10.1016/j.ejmech.2010.09.061. Epub 2010 Oct 7. Eur J Med Chem. 2010. PMID: 20974505

10

Synthesis and antitumor activity of epothilone B.

Cheng H, Huang H, Huang G. Cheng H, et al. Eur J Med Chem. 2018 Sep 5;157:925-934. doi: 10.1016/j.ejmech.2018.08.055. Epub 2018 Aug 23. Eur J Med Chem. 2018. PMID: 30149324 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,951 results

Search Page

Filters